CDC May Authorize Pfizer's COVID-19 Vaccine for Kids Next Week
The US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) has scheduled an 'emergency meeting' on May 12, 2021, without disclosing the agenda.
Various media reporters believe the ACIP will discuss the Pfizer - BioNTech COVID-19 vaccine's use for adolescents aged 12 to 15 years.
On May 4, 2021, New York-based Pfizer Inc. published its 'Key Near-term Potential Milestones for COVID-19 Vaccine Program (2021)' on slide #7 within its financial report. This slide indicates Pfizer's plan to obtain an Extended Use authorization during April 2021.
Pfizer and BioNTech SE announced on March 31, 2021, a Phase 3 trial in 2,260 adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection of the BNT162b2 vaccine demonstrated 100% efficacy and robust antibody responses and was well tolerated. On April 9, 2021, Pfizer requested that the current Emergency Use Authorization be amended to include teens between 12 and 15.
Furthermore, this slide indicates Pfizer anticipates receiving a U.S. FDA Biologics License in May'21 for its mRNA COVID-19 vaccine for people 16 and older. The experimental Pfizer-BioNTech COVID-19 mRNA vaccine was issued the first FDA Emergency Use Authorization for a vaccine to prevent COVID-19 on December 11, 2020.
Pfizer Inc. is an American multinational pharmaceutical corporation headquartered in New York City and is named after its co-founder, Charles Pfizer.